glp 1 inhibitors weight loss for More people with type diabetes are using GLP-1 drugs, study finds, despite limited evidence on safety or effectiveness Are Serious Anesthesia Risks of – Glucagon-like peptide-1 receptor agonists and

Researchers compared outcomes with users of another weight loss drug, bupropion-naltrexone (n = 654), and monitored all patients for development of biliary disease, pancreatitis, bowel obstruction or gastroparesis

Many people taking GLP-1 receptor agonists, such as semaglutide and tirzepatide, report decreased interest in alcohol

Athletic Performance & Recovery Optimisation Athletes, both recreational and competitive, are attracted to the possibility of quicker recovery between training, less downtime from injuries, and improved tissue resilience

On exposure to hypoxia, cancer cells undergo replication stress, thereby activating DNA damage and repair pathways

Notably, two new glucagon-like peptides were identified in intestinal extracts: GLP-1 and GLP-2